Literature DB >> 18855738

Recent advances in the research of HIV-1 RNase H inhibitors.

Fang Yu1, Xinyong Liu, Peng Zhan, Erik De Clercq.   

Abstract

Reverse transcription is a crucial step in the life cycle of human immunodeficiency virus type 1 (HIV-1). In this process, multiple functional enzymes including RNA-dependent DNA polymerase, DNA-dependent DNA polymerase and RNase H are indispensable. The RNase H functions to degrade RNA of the RNA-DNA heteroduplex into small fragment. These properties of HIV-1 RNase H make it an attractive target for rational anti-HIV-1 drug design and development. In this review, we summarized the HIV-1 RNase H inhibitors that were recently reported in the literature, including their chemical structure, mechanism and structure-activity relationship. It seems likely that HIV-1 RNase H as a prominent non-traditional target may lead to the development of anti-HIV agents which could be used alone or in the combination with other HIV inhibitors in AIDS chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18855738     DOI: 10.2174/138955708786141052

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  9 in total

1.  Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets.

Authors:  Catherine S Adamson; Eric O Freed
Journal:  Mol Interv       Date:  2009-04

2.  Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity.

Authors:  Catherine W Cai; Elena Lomonosova; Eileen A Moran; Xiaohong Cheng; Kunjan B Patel; Fabrice Bailly; Philippe Cotelle; Marvin J Meyers; John E Tavis
Journal:  Antiviral Res       Date:  2014-05-20       Impact factor: 5.970

Review 3.  Novel approaches to inhibiting HIV-1 replication.

Authors:  Catherine S Adamson; Eric O Freed
Journal:  Antiviral Res       Date:  2009-09-24       Impact factor: 5.970

Review 4.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

5.  Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H.

Authors:  Jayakanth Kankanala; Karen A Kirby; Andrew D Huber; Mary C Casey; Daniel J Wilson; Stefan G Sarafianos; Zhengqiang Wang
Journal:  Eur J Med Chem       Date:  2017-09-28       Impact factor: 6.514

6.  Identification of alternative binding sites for inhibitors of HIV-1 ribonuclease H through comparative analysis of virtual enrichment studies.

Authors:  Anthony K Felts; Krystal Labarge; Joseph D Bauman; Dishaben V Patel; Daniel M Himmel; Eddy Arnold; Michael A Parniak; Ronald M Levy
Journal:  J Chem Inf Model       Date:  2011-07-26       Impact factor: 4.956

7.  Inhibitors of HIV-1 Reverse Transcriptase-Associated Ribonuclease H Activity.

Authors:  Tatiana Ilina; Krystal Labarge; Stefan G Sarafianos; Rieko Ishima; Michael A Parniak
Journal:  Biology (Basel)       Date:  2012-10-19

8.  Metal and ligand binding to the HIV-RNase H active site are remotely monitored by Ile556.

Authors:  Xunhai Zheng; Geoffrey A Mueller; Eugene F DeRose; Robert E London
Journal:  Nucleic Acids Res       Date:  2012-08-31       Impact factor: 16.971

Review 9.  Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors.

Authors:  Lucianna Helene Santos; Rafaela Salgado Ferreira; Ernesto Raúl Caffarena
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-11       Impact factor: 2.743

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.